Novartis AG (VTX:NOVN) has received a consensus rating of “Hold” from the fifteen research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and seven have given a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is CHF 84.60.

Several equities analysts have commented on the stock. Deutsche Bank AG set a CHF 78 target price on shares of Novartis AG and gave the company a “neutral” rating in a report on Wednesday, June 21st. HSBC Holdings plc set a CHF 85 target price on shares of Novartis AG and gave the company a “buy” rating in a report on Wednesday, June 21st. Goldman Sachs Group, Inc. (The) set a CHF 80 target price on shares of Novartis AG and gave the company a “neutral” rating in a report on Wednesday, June 21st. Jefferies Group LLC set a CHF 100 target price on shares of Novartis AG and gave the company a “buy” rating in a report on Monday, June 5th. Finally, Barclays PLC set a CHF 65 target price on shares of Novartis AG and gave the company a “sell” rating in a report on Friday, June 2nd.

COPYRIGHT VIOLATION WARNING: This article was first published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/08/12/novartis-ag-vtxnovn-given-consensus-recommendation-of-hold-by-brokerages.html.

Shares of Novartis AG (NOVN) opened at 79.90 on Friday. The company has a 50-day moving average of CHK 80.97 and a 200-day moving average of CHK 77.44. The company has a market cap of CHK 187.20 billion and a PE ratio of 29.17. Novartis AG has a 1-year low of CHK 67.40 and a 1-year high of CHK 84.35.

Novartis AG Company Profile

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis AG (VTX:NOVN)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.